Adicet Bio (ACET)
(Delayed Data from NSDQ)
$1.17 USD
+0.10 (9.35%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $1.20 +0.03 (2.56%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 1 - 20 ( 104 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Phase 1 Trial of ADI-001 in Lupus Nephritis to Initiate This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EHA 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2024: ADI-270 Showing High Target Sensitivity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE- ASGCT 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Phase 1 GLEAN Study Continues to Enroll MCL Patients; ADI-001 Expanding into Autoimmune Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; ADI-001 and ADI-270 Remain on Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Model Update Following Raise; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From Clinical Pipeline and Corporate Outlook Conference Call
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expands to II via Lupus Nephritis; MCL New Focus
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expansion, Persistence, and Pharmacodynamic Profile Data From Phase 1 Study Highlighted at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Weekend Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D